Abstract |
Little is known about the cognitive factors associated with adherence to antiestrogen therapy. Our objective was to investigate the association between domain-specific cognitive function and adherence among women in a clinical prevention trial of oral antiestrogen therapies. We performed a secondary analysis of Co-STAR, an ancillary study of the STAR breast cancer prevention trial in which postmenopausal women at increased breast cancer risk were randomized to tamoxifen or raloxifene. Co-STAR enrolled nondemented participants ≥65 years old to compare treatment effects on cognition. The cognitive battery assessed global cognitive function (Modified Mini-Mental State Exam), and specific cognitive domains of verbal knowledge, verbal fluency, figural memory, verbal memory, attention and working memory, spatial ability, and fine motor speed. Adherence was defined by a ratio of actual time taking therapy per protocol ≥80% of expected time. Logistic regression was used to evaluate the association between cognitive test scores and adherence to therapy. The mean age of the 1,331 Co-STAR participants was 67.2 ± 4.3 years. Mean 3MS score was 95.1 (4.7) and 14% were nonadherent. In adjusted analyses, the odds of nonadherence were lower for those with better scores on verbal memory [OR (95% confidence interval): 0.75 (0.62-0.92)]. Larger relative deficits in verbal memory compared with verbal fluency were also associated with nonadherence [1.28 (1.08-1.51)]. Among nondemented older women, subtle differences in memory performance were associated with medication adherence. Differential performance across cognitive domains may help identify persons at greater risk for poor adherence.
|
Authors | Heidi D Klepin, Ann M Geiger, Hanna Bandos, Joseph P Costantino, Stephen R Rapp, Kaycee M Sink, Julia A Lawrence, Hal H Atkinson, Mark A Espeland |
Journal | Cancer prevention research (Philadelphia, Pa.)
(Cancer Prev Res (Phila))
Vol. 7
Issue 1
Pg. 161-8
(Jan 2014)
ISSN: 1940-6215 [Electronic] United States |
PMID | 24253314
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Copyright | ©2013 AACR. |
Chemical References |
- Anticarcinogenic Agents
- Tamoxifen
- Raloxifene Hydrochloride
|
Topics |
- Aged
- Anticarcinogenic Agents
(therapeutic use)
- Breast Neoplasms
(prevention & control)
- Cognition
(physiology)
- Cognition Disorders
(complications)
- Female
- Humans
- Logistic Models
- Medication Adherence
- Middle Aged
- Neuropsychological Tests
- Postmenopause
- Raloxifene Hydrochloride
(therapeutic use)
- Risk
- Tamoxifen
(therapeutic use)
|